Conor Lane

Grateful for an incredible experience at #TCT2025 — from presenting our latest research to connecting with mentors and catching up with friends. Huge thanks to @TCTMD @crfheart @MayoClinicCV @MayoCVFellows

Incredible weekend at #TCT2025! Grateful to be able to present our center's experience with novel approaches to coronary aneurysm management, and to be named among the best in show! Thankful to @rajivxgulati for his innovation and mentorship

This is a truly historic moment. The results from this pivotal trial evaluating a fully percutaneous transcatheter mitral valve replacement technology has opened a new treatment option for patients who are not good candidates for surgery or TEER. This is a remarkable milestone that will not only transform the field of interventional cardiology but, most importantly, will change the lives of countless patients who have been waiting for a viable treatment option. Slides presented as LBCT #TCT2025 today and link to our manuscript published @TheLancet today are included. Thank you to all the people who worked with us for a decade to make this happen! @DVDaniels @MayoClinicCV authors.elsevier.com/a/1l-xyV-4XSjay

The 10-year outcome of Noble trial may be the most impactful data presented at #TCT2025 PCI=CABG for isolated left main disease regardless of Syntax score Which isolated LM patients (suitable for PCI) will you refer to CABG?

The @MayoClinicCV & @MayoClinicCVS partners w/leading institutions in Mexico to perform North America’s first Silara MiBridgeTransseptal Direct Mitral Annuloplasty! Our groundbreaking Mayo team included Drs. Mayra Guerrero, Kimberly Holst, Sari Padang & Sorin Pislaru.

Genotype-Guided P2Y12i Monotherapy Within 7 Days of PCI in High Bleeding Risk Patients: The CHAMP Trial - Pilot Study & Safety Assessment 📝Genotype-guided P2Y12 inhibitor monotherapy within a week of PCI is feasible and likely safe in patients with HBR. sciencedirect.com/science/articl…

🎈Expanding LM bifurcation aneurysm 🎈Use of neuro web device 🎈#RadialFirst 🎈Hugely fortunate to work with and learn from talented colleagues @WBrinjikji @DrConorLane @MayoClinicCV

We evaluated 820 patients treated with TS MViR using the Sapien 3/Ultra/RESILIA THVs between Aug 2015 and Dec 2022 who were enrolled in the STS/ACC TVT Registry. We found a significant reduction in MR and sustained improvement in symptoms at 1 year. Mean mitral gradients were elevated at 30 days (7.9 ± 3.0 mmHg) and at 1 year (8.4 ± 3.4 mmHg), and reintervention rate was high at 1 year (9.1%). However, there was a significant improvement in quality of life which was sustained at 1 year (mean KCCQ score improvement at 30-day was 24.1 points and at 1 year was 25.9). TS MViR is a reasonable alternative for high-risk patients unable to undergo surgery who have favorable anatomy for MViR procedure. @MayoClinicCV Contemporary 1-Year Outcomes of Mitral Valve-in-Ring With Balloon-Expa... sciencedirect.com/science/articl…

🔍 Exciting findings from the AEGIS-II Trial are in! 🎉 Discover how this breakthrough therapy could redefine cardiovascular care with @CMichaelGibson💪 @accintouch @mayoclinic @DrConorLane @BaimInstitute #ACC2024 #ACCFIT #CardioTwitter youtu.be/cCWSu2bLzSE?si…

What a privilege to learn from some of the best in the business at #Fellows2024! Thanks again to @crfheart and all the faculty for this fantastic opportunity.

Check out this #JACCINT state-of-the-art review discussing the contemporary assessment and management of tricuspid regurgitation bit.ly/3Jf2VRw #vhdTR #CathLab @GarrettWelleMD @EleidMack @hahn_rt

The @MayoCVFellows family hanging out at @ACCinTouch #ACC24! A 💪🏻 first conference day, with countless presentations, posters, interviews, smiles, hugs, and general mischief 💓! Say hi if you see us! @MayoClinicCV @MayoClinic @FITsOnTheGo

@mandeep_mayo presents our findings from the CHAMP Trial. #Genotype-guided P2Y12 inhibitor monotherapy within a week of #PCI is feasible and likely safe in patients with #HBR. @rajivxgulati @ChetRihal @LermanAmir @nl_pereira @LinneaBaudhuin @AnnMoyerMDPhD #ACC2024 🫀🩸

Presented today at #ACC24: In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

Read 10 key points to remember from a state-of-the-art review on the clinical impact, predictors, classification, and management of device-related thrombus after LAAO: bit.ly/3GuZQv6

This #JACCINT study delves into the incidence, predictors, and clinical impact of persistent and recurrent #DRT post #LAAO 📊⚠️ bit.ly/47ThkNs @benhibbertMDPhD @hsuradi @AshishPershad @caresans26 @rachelkaplanmd

Great insights from the great @keaglemd at the @MayoCVFellows Fellowship Education Day #cvPrev

Can deep learning be utilized to estimate LVEF from routine coronary angiographic images? Read our latest publication sciencedirect.com/science/articl…

In patients w/ cardiovascular disease & overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 mos. Full SELECT trial results: nej.md/465pj91 #AHA23 @AHAScience

Congratulations to this year's ACC-MN FIT Jeopardy winners @DrConorLane, @Mahmoud_Ismayl and Dr. Samuel Huxley from @MayoCVFellows! #MCVF23